News
AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie ...
AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...
Capstan Therapeutics Inc. is a clinical-stage biotechnology company that specializes in developing CAR-T therapies. These therapies use a patient’s immune cells, specifically T-cells, to combat ...
AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...
US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate ...
AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...
Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo engineering ...
It has been a bumper week for biotech financings, with a $400m Series A for Mirador heading, topping impressive rounds for Capstan, Clasp, Engrail, Enliven, and Nouscom.
AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments ...
A new mRNA injection turns immune cells into cancer-fighting CAR-T cells — inside the body. Faster, cheaper, and potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results